[{"orgOrder":0,"company":"Vivani Medical","sponsor":"Nano Precision Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Second Sight Medical Products","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$55.0 million","newsHeadline":"Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic\u00ae\/Wegovy\u00ae and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Vivani's IND for NPM-119 Drug Implant","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Vivani Medical
NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.
NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.
Upon completion of the merger, the Company has to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes.
Nano Precision Medical, leveraging its proprietary NanoPortalTM drug implant technology, is creating a portfolio of new drugs including NPM’s lead program, NPM-119, that address medication non-adherence, a leading reason for poor clinical outcomes.